Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina

Internal Medicine

Volumn 47, Issue 1, 2008, Pages 7-13

  Sako, Hideto ^a   Miura, Shin Ichiro ^a   Iwata, Atsushi ^a   Nishikawa, Hiroaki ^a   Kawamura, Akira ^a   Matsuo, Kunihiro ^a   Shirai, Kazuyuki ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adhesion molecules; Bare metal stent; Chemokine receptors; Sirolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; METAL; MONOCYTE CHEMOTACTIC PROTEIN 1; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTERY OCCLUSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; IMPLANTATION; IN-STENT RESTENOSIS; MALE; MONOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; THROMBOSIS; TREATMENT RESPONSE;

AGED; ANGINA PECTORIS; AUTOANTIGENS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, CCR2; SIROLIMUS; STENTS;

EID: 38349014661     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0315     Document Type: Article

References (27)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323, 2003.
2. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111: 1040-1044, 2005.
3. Suzuki S, Kamihata H, Hata T, et al. Success rate of implantation and mid-term outcomes of the sirolimus-eluting stent. Circ J 71: 15-19, 2007.
4. Gaku N, Kengo, T, Aoki J, et al. Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice. Circ J 70: 1367-1371, 2006.
5. Nakamura M, Wada M, Hara H, Kozuma K, Otsuka Y, Miyazaki S. Angiographic and clinical outcomes of a pharmacokinetic study of sirolimus-eluting stents: lesson from restenosis cases. Circ J 69: 1196-1201, 2005.
6. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 524: 19-29, 2005.
7. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2: 95-101, 2001.
8. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12: 121-7, 2000.
9. Cipollone F, Marini M, Fazia M. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21: 327-334, 2001.
10. Horvath C, Welt FGP, Nedelman M. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 90: 488-494, 2002.
11. Kawamusa A, Miura S, Fujino, M, et al. CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease. Circ J 67: 851-854, 2003.
12. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96: 1102-1108, 1997.
13. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 315: 722-729, 1997.
14. Kamijikkoku S, Murohara T, Tayama S, et al. Acute myocardial infarction and increased soluble intercellular adhesion molecule-1: a marker of vascular inflammation and a risk of early restenosis? Am Heart J 136: 231-236, 1998.
15. Kawamura A, Miura S, Murayama T, et al. Increased expression of monocyte CD11a and intracellular adhesion molecule-1 in patients with initial atherosclerotic coronary stenosis. Circ J 68: 6-10, 2004.
16. Shirai K, Lansky AJ, Mintz GS, et al. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. Am J Cardiol 92: 1409-1413, 2003.
17. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 45: 308-311, 2005.
18. Nuhrenberg TG, Voisard R, Fahlisch F, et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 19: 246-249, 2005.
19. Schroppel B. Zhang N, Chen P, et al. Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. J Am Soc Nephrol 15: 1853-1861, 2004.
20. Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1 -dependent mechanism. J Immunol 171: 6929-6935, 2003.
21. Kochiadakis GE, Marketou ME, Arfanakis DA, et al. Reduced systemic inflammatory response to implantation of sirolimuseluting stents in patients with stable coronary artery disease. Atherosclerosis 194: 433-438, 2007.
22. Kitamoto S, Egashira K, Takeshita A. Stress and vascular responses: anti-inflammatory therapeutic strategy against atherosclerosis and restenosis after coronary intervention. J Pharmacol Sci 91: 192-196, 2003.
23. Ohtani K, Usui M, Nakano K, et al. Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther 11: 1273-1282, 2004.
24. Davis MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VACM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171: 223-229, 1993.
25. Zouridakis E, Avanzas P, Esliguero RA, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110: 1747-1753, 2004.
26. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque ruptures in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 106: 804-808, 2002.
27. Barringhaus KG, Phillips JW, Thatte JS, et al. α4β1 integrin (VLA-4) blocked attenuates both early and late leukocyte recruitment and neointimal growth following carotid injury in apolipoprotein E (-/-) mice. J Vasc Res 41: 252-260, 2004.